Survival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor
|
|
- Jonathan Milo Dawson
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 15: , 2009 ORIGINAL ARTICLE Survival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor Lei Yu, 1-3 Thomas Koepsell, 3 Lisa Manhart, 3 and George Ioannou 1,2 1 Division of Gastroenterology, Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA; 2 Research Enhancement Award Program, Veterans Affairs Puget Sound Health Care System, Seattle, WA; and 3 Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA Liver transplantation using grafts from donors with antibody against hepatitis B core antigen (anti-hbc) increases the recipients risk of developing hepatitis B virus (HBV) infection post-transplantation. Our aim was to assess whether using such grafts was associated with reduced posttransplantation survival and whether this association depended on recipients prior exposure to HBV on the basis of their pretransplantation serological patterns. Data were derived from the United Network for Organ Sharing on adult, cadaveric, first-time liver transplants performed between 1994 and Among recipients who did not have HBV infection before transplantation, those with anti-hbc positive donors had significantly worse unadjusted posttransplantation patient survival than recipients with anti-hbc negative donors [hazard ratio, 1.35; 95% confidence interval (CI), ]. However, after adjustments for other predictors of posttransplantation survival, including donor age, donor race, and recipient underlying liver diseases, patient survival was not significantly different between the 2 groups (hazard ratio, 1.09; 95% CI, ). Among recipients without antibody against hepatitis B surface antigen (anti-hbs), use of anti-hbc positive donor grafts was associated with a trend toward worse survival (adjusted hazard ratio, 1.18; 95% CI, ), whereas no such trend was observed among recipients positive for anti-hbs. In conclusion, in patients without HBV infection before transplantation, using anti-hbc positive donors was not independently associated with worse posttransplantation survival. Matching these donors to recipients with anti-hbs pre-transplantation may be especially safe. Liver Transpl 15: , AASLD. Received September 23, 2008; accepted March 10, See Editorial on Page 1164 Liver transplantation using grafts from donors positive for antibody against hepatitis B core antigen (anti-hbc) increases the recipients risk of hepatitis B virus (HBV) infection post-transplantation, as defined by the detection of hepatitis B surface antigen (HBsAg). 1-6 The underlying mechanism may be related to the observation that HBV can persist in the liver for many years after initial recovery, 7 and it can be reactivated in the setting Abbreviations: anti-hbc, antibody against hepatitis B core antigen; anti-hbs, antibody against hepatitis B surface antigen; BMI, body mass index; CI, confidence interval; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICU, intensive care unit; INR, international normalized ratio; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SD, standard deviation; UNOS, United Network for Organ Sharing. This research was based on data derived from the United Network for Organ Sharing on January 18, This research was supported by the American Liver Foundation and American Association for the Study of Liver Diseases through the Jan Albrecht Award (to G. Ioannou), by the Veterans Affairs Puget Sound Health Care System through the Research Enhancement Award Program (to L. Yu), by the National Institutes of Health through a T32 training grant (to L. Yu), and by the Health Resources and Services Administration (contract ). The content of this work is the responsibility of the authors alone and does not necessarily reflect the views or policies of the US Department of Health and Human Services. Address reprint requests to Lei Yu, M.D., Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box , Seattle, WA Telephone: ; leiy@medicine.washington.edu DOI /lt Published online in Wiley InterScience ( American Association for the Study of Liver Diseases.
2 1344 YU ET AL. of immunosuppression. 8 There are, however, conflicting data with respect to overall survival among these recipients. Dickson et al. 2 reported that 78% (18/23) of recipients with anti-hbc positive donor grafts developed HBV infection post-transplantation, with significantly decreased 4-year patient survival in comparison with recipients with anti-hbc negative grafts [hazard ratio, 2.4; 95% confidence interval (CI) ]. In contrast, Prieto et al. 3 did not find a survival difference between the 2 groups despite a similarly high frequency of HBV infection (50%, 15/30) among recipients with anti-hbc positive grafts. More recent studies have shown effective prophylaxis against HBV infection in recipients with anti-hbc positive grafts using lamivudine with or without hepatitis B immunoglobulin (HBIG), but few have analyzed patient or graft survival All of these studies involved a relatively small number of patients from selected transplant centers. No studies have adjusted for other important predictors of posttransplantation survival such as donor age, donor race, 16,17 cold ischemia time, 18,19 or recipient markers of liver disease severity. 17 Despite these uncertainties, anti-hbc positive donor livers continue to be used because of the current organ shortage, especially when the recipient is severely ill or has HBV-related cirrhosis. 3,9,20,21 With the exclusion of recipients with a pretransplantation diagnosis of HBV, it has been shown that when anti-hbc positive donor grafts were used in recipients who also harbored anti- HBc with or without antibody against hepatitis B surface antigen (anti-hbs), 2,3,5,6 there was a lower incidence of HBV infection post-transplantation. The protective effect of such matching, however, was not complete, 2,6 and the number of patients involved in these studies was too small for firm conclusions to be drawn. It also remains unclear whether posttransplantation survival was affected when anti-hbc positive donor livers were matched to anti-hbc positive or anti- HBs positive recipients. To more carefully examine these questions in a large and representative population, in the current study we aimed to assess whether anti-hbc positive donor grafts were associated with worse patient and graft survival following liver transplantation after adjustments for other important predictors of posttransplantation survival using data reported to the United Network for Organ Sharing (UNOS) from 1994 to We also aimed to assess whether this association depended on recipients prior exposure to HBV or vaccination on the basis of their pretransplantation HBV serological patterns. PATIENTS AND METHODS Study Design and Data Source We performed a retrospective cohort study using data compiled by UNOS. 22 Transplant centers in the United States are required to submit to UNOS standardized data collection forms, including the Transplant Candidate Registration Form, which contains patient information at the time of listing for liver transplantation, the Deceased Donor Registration Form, which contains information on all consented recovered and nonrecovered donors, the Transplant Recipient Registration Form, which includes the patient status at discharge, pretransplant and posttransplant clinical information, and treatment data, and the Transplant Recipient Follow-Up Form, which is generated 6 months post-transplant and on each subsequent transplant anniversary. The Transplant Recipient Follow-Up Form contains information on patient survival, clinical data, and treatment. After these forms are submitted to UNOS, the data are compiled into a single Standard Transplant Analysis and Research file. A detailed description of the UNOS database has been reported elsewhere. 23 We obtained a Standard Transplant Analysis and Research file from UNOS that included all liver transplants performed in the United States through January 18, Study Population Donor anti-hbc has been recorded on the Deceased Donor Registration form since April 1, 1994; we therefore included liver transplants performed between April 1, 1994 and January 18, We excluded recipients younger than 18 years of age (n 6568) and those who had donors under 10 years of age (n 568), living donors (n 1961), split-liver donors (n 717), non heart-beating donors (n 816), simultaneous organ transplants (n 1937), or previous liver transplants (n 4065). In our main analysis, we also excluded recipients who tested positive for HBsAg pre-transplantation or carried the diagnosis of HBV (n 2947). We additionally excluded transplants with donors who tested positive for HBsAg (n 50) or antibody against hepatitis C virus (HCV; n 850). Among the remaining 37,155 transplants, 4.1% (n 1535) had missing data on donor anti-hbc, and this left 35,620 transplants in the univariate analyses, including 1270 with positive donor anti-hbc. Patients with the diagnosis of HBV were analyzed separately, and a similar exclusion was applied to them as well. Definition of Outcomes Patient survival was measured in years from transplantation until death from any cause. Patients who remained alive or were lost to follow-up as of January 18, 2007 were censored at the time of last known follow-up for the analysis of patient survival. Graft survival was measured in years from transplantation until liver failure (with or without retransplantation) or patient death from any cause, whichever came first. Patients who remained alive without liver failure or were lost to follow-up as of January 18, 2007 were censored at the time of last known follow-up for the analysis of graft survival. Predictors of Posttransplantation Survival We assessed whether any observed differences in posttransplantation survival between recipients with and
3 SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION 1345 without anti-hbc positive donors were confounded by donor and recipient characteristics known to affect posttransplantation survival. 17 These included donor age, gender, and race and recipient age, gender, race, underlying liver diseases, and body mass index (BMI). Underlying liver diseases were based on diagnoses reported to UNOS after liver transplantation. Recipients who received exception scores for hepatocellular carcinoma (HCC) based on the more recent Model for End- Stage Liver Disease allocation system were characterized as having HCC instead of their primary liver disease. We included recipients serum albumin, total bilirubin, creatinine, and international normalized ratio (INR) at the time of transplantation as markers for liver disease severity. We also adjusted for the cold ischemia time, year of transplantation, and urgency of transplantation. We used recipient location prior to transplantation (intensive care unit, hospital ward, or home) as a surrogate marker for urgency. 24 Among recipients of anti-hbc positive donor grafts for whom data on lamivudine or HBIG use were available (n 374 in ), we also assessed the potential effect of these treatments on patient survival. Effect Modification Among recipients without a pretransplantation diagnosis of HBV, we tested whether any survival difference between recipients with and without anti-hbc positive donors depended on recipient HBV serological patterns. Routinely tested recipient HBV serological markers include anti-hbc and anti-hbs with 4 potential patterns: (1) anti-hbs negative and anti-hbc negative, indicating a lack of evidence of prior HBV exposure; (2) anti- HBs negative and anti-hbc positive, indicating possible prior exposure; (3) anti-hbs positive and anti-hbc negative, indicating HBV vaccination; and (4) anti-hbs positive and anti-hbc positive, indicating recovered HBV infection. We also tested whether any survival difference between recipients with and without anti- HBc positive donors depended on recipients diagnosis of hepatitis C infection pre-transplantation. Statistical Analysis Cox proportional hazards regression was used to compare patient and graft survival in recipients with and without anti-hbc positive donors before and after adjustments for other predictors of posttransplantation survival. 25 The assumption of proportional hazards was tested by graphical and weighted residual methods. In the multivariate analysis, we decided a priori to include all predictors of posttransplantation survival except INR, which was not recorded in close to 50% of recipients during the study period. Given that the mean INR was not significantly different between the 2 exposure groups, its inclusion would have resulted in a loss of sample size and precision. All predictors were modeled continuously except for gender, race, underlying liver diseases, pretransplantation location, and transplantation year categories ( , , , and ). Trends in anti-hbc positive donor use over the 13-year study period were assessed with the chi-square test for trends. The Kaplan- Meier method was used to estimate patient survival at 1 year among recipients who received an anti-hbc positive graft between 2004 and For these recipients, the log-rank test was used to compare survival between those who were and those who were not using lamivudine or HBIG. We also performed the same univariate and multivariate analyses among recipients who carried the diagnosis of HBV pre-transplantation (excluded in the primary study population) to assess the effect of anti-hbc positive donor organs on their survival. All analyses were performed with STATA 9.0 software (Stata Corp., College Station, TX). To simultaneously adjust for multiple predictors of posttransplantation survival in multivariate analyses, we excluded transplants with missing data for the following characteristics: recipient BMI (n 1007), creatinine (n 303), total bilirubin (n 459), albumin (n 808), and cold ischemia time (n 3691). We also excluded 659 transplants with very abnormal data (because they might have been recorded erroneously) and 170 transplants with implausible data (almost certainly recorded erroneously), as defined in the next paragraph; this left 28,494 transplants in the multivariate analyses, including 997 with positive donor anti-hbc. Transplants with missing data on both recipient anti- HBc and recipient anti-hbs were further excluded (n 7465) when we examined their effect on the relationship between donor anti-hbc status and posttransplantation survival. After these exclusions, the distribution of important confounding variables based on donor anti- HBc status, such as recipient age and BMI, donor age, and recipient liver disease etiologies, remained similar to the distribution before these exclusions. Very abnormal values were defined as follows: cold ischemia time, 0.5 to 1or 24 to 48 hours; BMI, 10 to 15 or 55 to 65 kg/m 2 ; serum creatinine, 0 to 0.1 or 15 to 20 mg/dl; serum total bilirubin, 0 to 0.1 or 45 to 100 mg/dl; and serum albumin, 0to 0.5 or 6 to 10 g/dl. Implausible data were even more extreme than the very abnormal values. RESULTS Among recipients without a pretransplantation diagnosis of HBV infection, anti-hbc positive donors accounted for 3.6% (1270/35,620) of adult, cadaveric, first-time liver transplants from 1994 to This increased significantly from 1.8% in 1994 to 6.0% in 2006 (P 0.001; Fig. 1). Among 11 UNOS regions, the proportion of transplants involving anti-hbc positive donors ranged from 1.2% to 8.5% (P 0.001). Compared to recipients with anti-hbc negative donors, recipients with anti-hbc positive donors had similar pretransplantation mean BMI, albumin, creatinine, and INR. The 2 groups, however, had significantly different underlying liver diseases (P 0.001; Table 1). Most strikingly, recipients with anti-hbc positive donors had a higher proportion of HCV infection (41.2% versus
4 1346 YU ET AL. Figure 1. Proportion of liver transplant recipients who did not have hepatitis B virus infection pre-transplantation with antibody against hepatitis B core antigen positive donors (April 1994 to January 2006). 32.9%) and HCC (15.5% versus 10.2%) and a lower proportion of cholestatic liver diseases (5.3% versus 12.4%). Recipients with anti-hbc positive donor grafts were also more likely to harbor anti-hbc themselves with (25.5% versus 9.1%) or without (17.6% versus 8.5%) anti-hbs (P 0.001; Table 1). Compared to anti- HBc negative donors, anti-hbc positive donors were older (mean age, versus years; P ) and more likely to be black (26.6% versus 11.5%; P 0.001). Before adjustments for other predictors of posttransplantation survival, recipients with anti-hbc positive donors had significantly worse patient survival than those with anti-hbc negative donors (hazard ratio, 1.35; 95% CI, ; Table 2). After adjustments for other predictors of posttransplantation survival, patient survival was not significantly different between the 2 groups (hazard ratio, 1.09; 95% CI, ). Similar results were found for graft survival. Although anti-hbc positive donor organs appear to affect recipients without HCV infection (hazard ratio, 1.46; 95% CI, ) more adversely than recipients with HCV infection (hazard ratio, 1.17; 95% CI, ) in the univariate analysis, this effect was not significant after adjustments for other predictors of survival (hazard ratio, 1.10, and 95% CI, for recipients without HCV; hazard ratio, 1.06, and 95% CI, for recipients with HCV). Although using grafts from anti-hbc positive donors did not significantly influence adjusted patient (Table 3) or graft survival (data not shown) in any subgroup of recipients on the basis of their HBV serological patterns, use of such grafts appeared to affect recipients without anti-hbs more adversely than those with anti- HBs (Table 3). We did not observe a higher matching rate (anti-hbc positive donors with anti-hbc positive or anti-hbs positive recipients) in more recent years (data not shown). Since 2004, data with respect to the use of lamivudine and HBIG became available in the UNOS database. From January 1, 2004 through January 18, 2006, 374 recipients who did not have a pretransplantation diagnosis of HBV infection received anti-hbc positive donor grafts. Among them, 24.5% (92/374) received either lamivudine or HBIG. The use of these medications was not associated with recipient anti-hbc or anti-hbs status. One-year survival was not significantly different between those who were using lamivudine or HBIG and those who were not (94.1% versus 88.6% respectively, P 0.9). Among recipients with HBV infection pre-transplantation (n 2797), 387 (13.8%) received anti-hbc positive donor organs. There was no apparent adverse effect on patient survival related to anti-hbc positive donor organs before (hazard ratio, 0.90; 95% CI, ) or after (hazard ratio, 1.06; 95% CI, ) adjustments for other predictors of posttransplantation survival. DISCUSSION Using comprehensive clinical data from UNOS, we did not find a significant association between use of anti- HBc positive donors and posttransplantation patient or graft survival after adjusting for other predictors of posttransplantation survival. Among recipients without HBV infection pre-transplantation, older donor age, a higher proportion of donor black race, 16 and a higher proportion of recipient HCV and HCC, 24 which are known risk factors for decreased posttransplantation survival, likely confounded the association between anti-hbc positive donors and worse survival observed in the univariate analysis. Among recipients without HBV infection pre-transplantation, a number of small studies have suggested that the rate of posttransplantation HBV infection varies, depending on recipients HBV serological patterns as indications of prior exposure or vaccination. 2,3,5,6 The rate of infection among recipients negative for both anti-hbc and anti-hbs has ranged from 38% (3/8) 4 to 100% (3/3) 6 versus the range of 0% (0/2 2 and 0/4 3 )to 13% (2/15) 5 among recipients positive for anti-hbc. The protective effect of anti-hbs has been similarly varied, with infection rates ranging from 0% (0/7, 5 0/2, 3 and 0/13 6 ) to 33% (1/3). 2 Despite the small number of patients involved, several studies have advocated actively matching anti-hbc positive donors to recipients with serological evidence of HBV exposure or vaccination. 3,5,6 The effect of this strategy was evident in the current study, in which recipients with anti-hbc positive grafts were much more likely to harbor anti-hbc with or without anti-hbs pre-transplantation (Table 1). We wanted to test whether the potential benefit of matching in reducing posttransplantation HBV infection translates into improved patient and graft survival among recipients without HBV infection pre-transplantation. Using a much larger sample than prior studies, we found no significant association between use of anti- HBc positive donors and posttransplantation survival, regardless of recipients HBV serological patterns (Table 3). One possibility is that despite the large sample size,
5 SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION 1347 TABLE 1. Characteristics of Liver Transplant Recipients Without HBV Infection Pre-Transplantation by Donor Anti-HBc Status Total (n 35,620) Anti-HBc Negative Donor (n 34,350) Anti-HBc Positive Donor (n 1270) P Value Age (years, mean SD) BMI (kg/m 2, mean SD) Laboratory studies at transplant Creatinine (mg/dl, mean SD) Total bilirubin (mg/dl, mean SD) INR (mean SD) Albumin (g/dl, mean SD) Male (%) Race (%) White Black Hispanic Asian Other Underlying liver disease (%) HCV Alcohol NASH Cryptogenic PBC and PSC Autoimmune Heptocellular carcinoma Cholangiocarcinoma Fulminant Other HBV serology (%) Anti-HBs negative, anti-hbc negative Anti-HBs negative, anti-hbc positive Anti-HBs positive, anti-hbc negative Anti-HBs positive, anti-hbc positive Cold ischemia time (hours, mean SD) Causes of death 0.09 Cardiovascular Rejection Infection Malignancy Biliary Vascular Hepatitis Other Location before transplant (%) 0.06 Home Ward ICU Other Donor age (years, mean SD) Donor male (%) Donor race (%) White Black Hispanic Asian Other Transplant year (%) April 1994 to December January 98 to December January 01 to December January 04 to January Abbreviations: anti-hbc, antibody against hepatitis B core antigen; anti-hbs, antibody against hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; ICU, intensive care unit; INR, international normalized ratio; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SD, standard deviation.
6 1348 YU ET AL. TABLE 2. Association Between Donor Anti-HBc Status and Posttransplant Patient and Graft Survival Among Recipients Without HBV Infection Pre-Transplantation Total (n 35,620) Anti-HBc Negative Donor (n 34,350) Anti-HBc Positive Donor (n 1270) Follow-up length (patient years) 130,428 3,962 Patient deaths 8, Mortality per 100 patient years Unadjusted hazard ratio (95% CI) for patient survival ( ) Adjusted hazard ratio (95% CI) for patient survival* ( ) Unadjusted hazard ratio (95% CI) for graft survival ( ) Adjusted hazard ratio (95% CI) for graft survival* ( ) Abbreviations: anti-hbc, antibody against hepatitis B core antigen; CI, confidence interval; HBV, hepatitis B virus. *Adjusted for donor age, gender, and race; recipient age, gender, race, underlying liver diseases, body mass index, serum albumin, creatinine, total bilirubin at the time of transplant, and location before transplant; transplant year; and cold ischemia time. TABLE 3. Association Between Donor anti-hbc Status and Posttransplant Patient Survival in 4 Groups of Recipients Without HBV Infection Pre-Transplantation on the Basis of Their HBV Serology Recipient HBV Serology Anti-HBs Negative, Anti-HBc Negative (n 15,111) Anti-HBs Negative, Anti-HBc Positive (n 1947) Anti-HBs Positive, Anti-HBc Negative (n 1880) Anti-HBs Positive, Anti-HBc Positive (n 2091) Anti-HBc negative donor (n 20,273) 14, Anti-HBc positive donor (n 756) Unadjusted hazard ratio (95% CI) 1.32 ( ) 1.43 ( ) 1.01 ( ) 0.95 ( ) Adjusted hazard ratio (95% CI)* 1.18 ( ) 1.22 ( ) 0.84 ( ) 0.86 ( ) Abbreviations: anti-hbc, antibody against hepatitis B core antigen; anti-hbs, antibody against hepatitis B surface antigen; CI, confidence interval; HBV, hepatitis B virus. *Adjusted for donor age, gender, and race; recipient age, gender, race, underlying liver diseases, body mass index, serum albumin, creatinine, total bilirubin at the time of transplant, and location before transplant; transplant year; and cold ischemia time. we did not have sufficient statistical power to detect small differences in survival, especially in the groups of recipients negative for anti-hbs with or without anti- HBc. In these 2 groups, recipients of anti-hbc positive donor grafts had approximately 20% worse patient survival after adjustments for important confounders, but this did not reach statistical significance (Table 3). An alternative explanation may be that matching does reduce the risk of posttransplantation HBV, but it does not affect overall survival because effective prophylaxis now exists even when matching is not feasible Dodson et al. 9 first reported 100% success using a combination of lamivudine and HBIG to prevent posttransplantation HBV infection (0/15) among recipients who received an anti-hbc positive graft with a mean follow-up of 15 months. Eight of these 15 patients were negative for both anti-hbc and anti-hbs. Yu et al. 10 subsequently reported similar success using lamivudine alone with a mean duration of follow-up of 17 months. A study from Taiwan, where the prevalence of anti-hbc positive donors was 63%, reported an incidence of posttransplantation HBV of 44% (7/16) without lamivudine versus 0% (0/44) with lamivudine among recipients with anti-hbc positive grafts. 26 Even though none of these studies were randomized and there are currently no published guidelines for prophylaxis against HBV infection post-transplantation when anti-hbc positive grafts are used, these overwhelmingly positive results likely increased the practice of prophylaxis. In the current study, close to 25% of recipients of an anti-hbc positive graft were using lamivudine or HBIG in recent years, but there was no significant difference in patient survival at 1 year. Although this may represent a real lack of survival benefit attributable to prophylaxis despite its efficacy in preventing posttransplantation HBV, it is also possible that a survival difference becomes apparent only with longer follow-up. Future studies should focus on longterm effects of prophylaxis on survival as well as the possibility of viral resistance, which has been reported with lamivudine. 27 Finally, anti-hbc positive donor grafts may not lead
7 SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION 1349 to worse survival because posttransplantation HBV infection has a mild clinical course and is treatable. The severity of posttransplantation HBV infection was first described by Wachs et al., 1 who reported that, of 3 recipients who developed the infection post-transplantation, 1 died of liver failure within 1 year, 1 had cirrhosis, and 1 had active chronic hepatitis; all were presumably related to HBV. 1 Subsequent studies, however, have suggested a less worrisome outcome. Manzarbeitia el al. 6 reported that of 5 recipients who developed HBV, only 2 had mild allograft dysfunction. Both were successfully treated with lamivudine alone or in conjunction with HBIG. Similarly, 12 of 15 Spanish patients with posttransplantation HBV were alive with a median follow-up of 39 months, whereas the other 3 patients died of non HBV-related causes. The study also reported good virological response to lamivudine. 3 A recent review suggested that anti-hbc positive donor grafts may be used to expand donor availability without mentioning specific criteria for matching with recipient HBV serology or clinical status. 28 This more liberal approach is evident in the current study (Fig. 1), likely reflecting the combined effect of the organ shortage 29 and the relatively benign clinical outcome associated with anti-hbc positive grafts observed more recently. 3,5,6,9,13 There are, however, significant variations in the rate of anti-hbc positive donor graft usage among US transplant regions, as we have observed. According to a survey published in 2003, only 57% of transplant centers would consider using anti-hbc positive donors in recipients without serological evidence of prior exposure to HBV. 20 Our finding substantiates the growing body of evidence that anti-hbc positive donors may be used safely with patient and graft survival comparable to those observed with anti-hbc negative donors. Such information is important for transplant physicians when communicating with potential recipients. Currently, the prevalence of anti-hbc in the general population is estimated to be between 4.3% and 5.4%, 30 which is similar to the proportion of recipients with anti-hbc positive donors in recent years. There are, however, no data on whether the prevalence of anti-hbc among organ donors in the United States is similar to that of the general population. It is also unclear how many anti-hbc positive donor livers remain unused. Our study has several limitations, the most important being the inability to assess the rate of posttransplantation HBV infection, as defined by the detection of HBsAg after transplantation in patients who were negative before transplantation. This variable, which is documented in the Transplant Recipient Follow-Up Form, unfortunately was not reported for more than 80% of recipients. Knowing accurately the rate of HBV infection would have allowed us to determine whether the lack of survival disadvantage was a result of prevention of posttransplantation HBV by matching (or prophylaxis) or a result of a mild clinical course despite the presence of posttransplantation HBV. Second, the UNOS database did not have data on serum or liver HBV DNA, which may be useful in determining recipients risk of developing HBV when anti-hbc positive grafts were used. 13 Furthermore, even though UNOS has been reporting lamivudine use since 2004, it is unclear from the database whether it is for the purpose of prophylaxis or active treatment of posttransplantation HBV. Finally, a fair number of patients had to be excluded because of missing data for 1 or more covariates for multivariate analyses, so technically the results apply only to those with complete data. Our study also has several important strengths. Even though the association between anti-hbc positive donors and posttransplantation HBV is well established, 1-6 there are conflicting data on the overall survival experience among recipients. UNOS, which contains all liver transplants performed in the United States, offered an opportunity to analyze the largest and most representative sample of patient and graft survival to date. Despite the exclusion of recipients with incomplete data, there remained more than 20,000 recipients, of which close to 1000 received anti-hbc positive organs, in the multivariate analysis (see the Patients and Methods section). UNOS collects detailed pretransplantation variables that are known predictors of posttransplantation survival; our ability to adjust for these variables provides a less confounded assessment of the true effect of donor anti-hbc positivity on recipient outcome. Finally, the effect of recipient HBV pretransplantation serological patterns was tested in an a priori fashion; the sample size again allows a firmer conclusion to be drawn in comparison with prior studies. Although the aforementioned limitations affected our ability to confirm reasons behind our findings, they do not affect the validity of our primary analysis of patient and graft survival. In conclusion, the findings of the current study are reassuring for recipients of anti-hbc positive donor grafts as they, on average, have survival times similar to those with anti-hbc negative donor grafts when other predictors of posttransplantation survival are taken into account. The use of such grafts is certainly safe among recipients with HBV infection pre-transplantation. For recipients without HBV infection pre-transplantation, matching these grafts with those who have anti-hbs prior to transplantation, as a result of either vaccination or prior exposure to HBV, may be especially safe. These data may be useful for future liver transplant recipients and their physicians in the organ allocation process. REFERENCES 1. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg( ), HBcAb( ), HBIgM( ) organ donors. Transplantation 1995;59: Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113: Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM,
8 1350 YU ET AL. Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-hbc positivity in the donor population. Liver Transpl 2001;7: Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997;3: Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64: Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002;8: Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;94: Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100: Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-hbc positive donors. Transplantation 1999;68: Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001;7: Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002;137: ; discussion Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-hbc positive donors. Gut 2002;50: Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-hbc) in the era of prophylaxis with hepatitis-b immunoglobulin and lamivudine. Transplantation 2003;75: Hoofnagle JH, Lombardero M, Zetterman RK, Lake J, Porayko M, Everhart J, et al. Donor age and outcome of liver transplantation. Hepatology 1996;24: Busquets J, Xiol X, Figueras J, Jaurrieta E, Torras J, Ramos E, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation 2001;71: Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6: Ioannou GN. Development and validation of a model predicting graft survival after liver transplantation. Liver Transpl 2006;12: Furukawa H, Todo S, Imventarza O, Casavilla A, Wu YM, Scotti-Foglieni C, et al. Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation 1991;51: Totsukali E, Fung JJ, Ishizawa Y, Nishimura A, Ono H, Toyoki Y, et al. Synergistic effect of cold and warm ischemia time on postoperative graft outcome in human liver transplantation. Hepatogastroenterology 2004;51: Burton JR Jr, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003;9: Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002;8:S82 S United Network for Organ Sharing. Available at: Accessed March Dickinson DM, Bryant PC, Williams MC, Levine GN, Li S, Welch JC, et al. Transplant data: sources, collection, and caveats. Am J Transplant 2004;4(suppl 9): Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122: Cox D. Regression models and life tables. J R Stat Soc Ser B 1972;34: de Villa VH, Chen YS, Chen CL. Hepatitis B core antibodypositive grafts: recipient s risk. Transplantation 2003;75: S49 S Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC. Case report of lamivudineresistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006;6: Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9: Annual Report of the Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data Available at: Accessed March Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. Incidence of hepatitis B virus infection in the United States, : estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998;178:
Survival of Liver Transplant Recipients With Hemochromatosis in the United States
GASTROENTEROLOGY 2007;133:489 495 Survival of Liver Transplant Recipients With Hemochromatosis in the United States LEI YU*, and GEORGE N. IOANNOU*, *Division of Gastroenterology, Department of Medicine
More informationAntibody to Hepatitis B Core Antigen Positive Grafts: Not Perfect but No Longer Marginal
LIVER TRANSPLANTATION 15:1164-1168, 2009 EDITORIAL Antibody to Hepatitis B Core Antigen Positive Grafts: Not Perfect but No Longer Marginal Martín Prieto Hepatogastroenterology Service, Hospital Universitario
More informationDonor organ shortages occasionally mandate the
Active Immunization Against De Novo Hepatitis B Virus Infection in Pediatric Patients After Liver Transplantation Seong-Hwan Chang, 1 Kyung-Suk Suh, 1 Nam-Joon Yi, 1 Seok Ho Choi, 1 Hoan Jong Lee, 2 Jeong
More informationDe novo hepatitis B infection acquired during liver transplantation
Q JMed 2001; 94:271±275 De novo hepatitis B infection acquired during liver transplantation P.J. GOW and D.J. MUTIMER From the Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, UK Received
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationPAPER. Use of Hepatitis B Core Antibody Positive Donors in Orthotopic Liver Transplantation. transplantation (OLT) experience
PAPER Use of Hepatitis B Core Antibody Positive Donors in Orthotopic Liver Transplantation David Holt, MD; Ryan Thomas, BS; David Van Thiel, MD; John J. Brems, MD Hypothesis: Hepatic allografts from donors
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationL iver transplantation is the major treatment for patients
95 LIVER AND BILIARY DISEASE Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-hbc positive donors A M Roque-Afonso, C Feray, D Samuel, D Simoneau,
More informationSurvival Outcomes Following Liver Transplantation (SOFT) Score: A Novel Method to Predict Patient Survival Following Liver Transplantation
American Journal of Transplantation 2008; 8: 2537 2546 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationIn the last years, an increasing number of apparently
Evidence of Serious Graft Damage Induced by De Novo Hepatitis B Virus After Liver Transplantation Roberto Segovia, * Alberto Sánchez-Fueyo, * Antoni Rimola, * Luis Grande, Miquel Bruguera, * Josep Costa,
More informationMinimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
LIVER TRANSPLANTATION 16:130-137, 2010 ORIGINAL ARTICLE Minimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
More informationThe Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C
LIVER TRANSPLANTATION 15:1126-1132, 2009 ORIGINAL ARTICLE The Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C Phillip S. Pang, 1,2 * Ahmad
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationORIGINAL ARTICLE. Robert Perrillo Hepatology Division, Baylor University Medical Center, Dallas, TX
LIVER TRANSPLANTATION 15:223-232, 2009 ORIGINAL ARTICLE Hepatitis B Virus Prevention Strategies for Antibody to Hepatitis B Core Antigen Positive Liver Donation: A Survey of North American, European, and
More informationDe novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2015.89.3.145 Annals of Surgical Treatment and Research De novo hepatitis B virus infection developing after liver transplantation
More informationResearch Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Transplantation Volume 2013, Article ID 269096, 7 pages http://dx.doi.org/10.1155/2013/269096 Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients:
More informationHepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses
Hepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses Mario G. Pessoa,*00 Norah A. Terrault,*00 Linda D. Ferrell, Jill Detmer, Janice Kolberg, Mark L. Collins, Maurene Viele,
More informationCirrhosis secondary to chronic hepatitis C viral
Effect of Alcoholic Liver Disease and Hepatitis C Infection on Waiting List and Posttransplant Mortality and Transplant Survival Benefit Michael R. Lucey, 1 Douglas E. Schaubel, 2,3 Mary K. Guidinger,
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationSpontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report
Hara et al. Surgical Case Reports (2016) 2:118 DOI 10.1186/s40792-016-0246-2 CASE REPORT Open Access Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis
More informationLiver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database
Title Liver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database Author(s) Zheng, J; Xiang, J; Zhou, J; Li, Z; Hu, Z; Lo, CM; Wang,
More informationThe Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database
LIVER TRANSPLANTATION 12:652-658, 2006 ORIGINAL ARTICLE The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database Victor Navarro,
More informationLiver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract
Indication and Prognosis of Liver Transplantation Jae Won Joh, M.D. Department of General Surgery Sungkyunkwan University School of Medicine Samsung Medical Center E mail: jwjoh@smc.samsung.co.kr Abstract
More informationIn the United States, the Model for End-Stage Liver. Re-weighting the Model for End-Stage Liver Disease Score Components
GASTROENTEROLOGY 2008;135:1575 1581 Re-weighting the Model for End-Stage Liver Disease Score Components PRATIMA SHARMA,* DOUGLAS E. SCHAUBEL,, CAMELIA S. SIMA,, ROBERT M. MERION,, and ANNA S. F. LOK* *Division
More informationORIGINAL ARTICLE. Received April 30, 2007; accepted June
LIVER TRANSPLANTATION 13:1405-1413, 2007 ORIGINAL ARTICLE Human Leukocyte Antigen and Adult Living- Donor Liver Transplantation Outcomes: An Analysis of the Organ Procurement and Transplantation Network
More informationGeographic Differences in Event Rates by Model for End-Stage Liver Disease Score
American Journal of Transplantation 2006; 6: 2470 2475 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant
More informationCadaver Donor Screening for Infectious Agents in Solid Organ Transplantation
781 SPECIAL SECTION: INFECTIONS IN TRANSPLANTATION AND OTHER IMMUNOCOMPROMISED HOSTS David R. Snydman, Section Editor Cadaver Donor Screening for Infectious Agents in Solid Organ Transplantation Francis
More informationRecurrence of hepatitis C virus (HCV) after orthotopic. Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame?
RAPID COMMUNICATION Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame? Kymberly D.S. Watt, Elizabeth R. Lyden, and Timothy M. McCashland Data from 1990 to 1996 suggest that the prevalence
More informationLiver Transplantation Using Donation After Cardiac Death Donors: Long-Term Follow-Up from a Single Center
American Journal of Transplantation 2009; 9: 773 781 Wiley Periodicals Inc. C 2009 The Authors Journal compilation C 2009 The American Society of Transplantation and the American Society of Transplant
More informationLong-term Outcomes After Third Liver Transplant
ArtıcLe Long-term Outcomes After Third Liver Transplant C. Burcin Taner, 1 Deniz Balci, 1 Darrin L. Willingham, 1 Andrew P. Keaveny, 1 Barry G. Rosser, 1 Juan M. Canabal, 1 Timothy S. J. Shine, 2 Denise
More informationFrequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationFor the past two decades, the number of patients
When Shouldn t We Retransplant? Michael A. Zimmerman and R. Mark Ghobrial Key Points 1. In the setting of early graft failure after primary transplantation, orthotopic liver retransplantation (re-olt)
More informationWaitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach
American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530
More informationExperience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010
Original articles Experience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010 Octavio Muñoz, MD, 1 Laura Ovadía, MD,
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationDonor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation
8 Original Article Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation Neema Kaseje 1 Samuel Lüthold 2 Gilles Mentha 3 Christian Toso 3 Dominique Belli 2 Valérie McLin 2 Barbara
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationRemoving Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs
LIVER TRANSPLANTATION 14:303-307, 2008 ORIGINAL ARTICLE Removing Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs Kevin P. Charpentier 1 and Arun Mavanur 2 1 Rhode
More informationPAPER. Liver Transplant for Hepatitis C Virus. Effect of Using Older Donor Grafts on Short- and Medium-Term Survival
PAPER Liver Transplant for Hepatitis C Virus Effect of Using Older Donor Grafts on Short- and Medium-Term Survival M. B. Majella Doyle, MD; Christopher D. Anderson, MD; Neeta Vachharajani, MD; Jeffrey
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationDiabetes, Hypertension and Hyperlipidemia: Prevalence Over Time and Impact on Long-Term Survival After Liver Transplantation
American Journal of Transplantation 2012; 12: 2181 2187 Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04077.x
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More informationHwm YI Yoo, * Ernest0 Molmenti, ' and PuulJ Tbuluvutb"
The Effect of Donor Body Mass Index on Primary Nonfunction, Retransplantation Rate, and Early and Patient Survival After Liver Transplantation Hwm YI Yoo, * Ernest0 Molmenti, ' and PuulJ Tbuluvutb" Previous
More informationORIGINAL ARTICLE. Did the New Liver Allocation Policy Affect Waiting List Mortality?
ORIGINAL ARTICLE Model for End-stage Liver Disease Did the New Liver Allocation Policy Affect Waiting List Mortality? Mary T. Austin, MD, MPH; Benjamin K. Poulose, MD, MPH; Wayne A. Ray, PhD; Patrick G.
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationPrimary sclerosing cholangitis (PSC) is a chronic
Predicting Clinical and Economic Outcomes After Liver Transplantation Using the Mayo Primary Sclerosing Cholangitis Model and Child-Pugh Score Jayant A. Talwalkar, * Eric Seaberg, W. Ray Kim, * and Russell
More informationObesity is perhaps the most significant public health problem
Obesity and Its Effect on Survival in Patients Undergoing Orthotopic Liver Transplantation in the United States Satheesh Nair, 1 Sumita Verma, 2 and Paul J. Thuluvath 2 Studies assessing morbidity and
More informationLIVER TRANSPLANTATION HAS ADvanced
ORIGINAL CONTRIBUTION Resource Utilization in Liver Transplantation Effects of Patient Characteristics and Clinical Practice Jonathan Showstack, PhD, MPH Patricia P. Katz, PhD John R. Lake, MD Robert S.
More informationCombined Effect of Donor and Recipient Risk on Outcome After Liver Transplantation: Research of the Eurotransplant Database
LIVER TRANSPLANTATION 21:1486 1493, 2015 ORIGINAL ARTICLE Combined Effect of Donor and Recipient Risk on Outcome After Liver Transplantation: Research of the Eurotransplant Database Joris J. Blok, 1 Hein
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationShould Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores < 14 Be Avoided? A Decision Analysis Approach
LIVER TRANSPLANTATION 15:242-254, 2009 ORIGINAL ARTICLE Should Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores < 14 Be Avoided? A Decision Analysis Approach James D. Perkins,
More informationPancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationFollowing the introduction of adult-to-adult living
LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION Liver Transplant Recipient Survival Benefit with Living Donation in the Model for Endstage Liver Disease Allocation Era Carl L. Berg, 1 Robert M. Merion, 2 Tempie
More informationORIGINAL ARTICLE. Received December 19, 2005; accepted October 18, 2006.
LIVER TRANSPLANTATION 13:451-458, 2007 ORIGINAL ARTICLE Recurrence of Hepatitis B Is Associated With Cumulative Corticosteroid Dose and Chemotherapy Against Hepatocellular Carcinoma Recurrence After Liver
More informationHBV, HCV, HIV and Kidney Transplantation. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
HBV, HCV, HIV and Kidney Transplantation Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Objectives Prevalence of hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationORIGINAL ARTICLE. Hung-Tien Kuo, 1,2 Erik Lum, 1 Paul Martin, 3 and Suphamai Bunnapradist ORIGINAL ARTICLE
ORIGINAL ARTICLE Effect of Diabetes and Acute Rejection on Liver Transplant Outcomes: An Analysis of the Organ rocurement and Transplantation Network/United Network for Organ Sharing Database Hung-Tien
More informationHospital Utilization of Nationally Shared Liver Allografts from A thesis submitted to the. Graduate School. of the University of Cincinnati
Hospital Utilization of Nationally Shared Liver Allografts from 2009-2012 A thesis submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationPredicted Lifetimes for Adult and Pediatric Split Liver Versus Adult Whole Liver Transplant Recipients
American Journal of Transplantation 2004; 4: 1792 1797 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00594.x Predicted Lifetimes for Adult and Pediatric Split
More informationClinical Study The Impact of the Introduction of MELD on the Dynamics of the Liver Transplantation Waiting List in São Paulo, Brazil
Transplantation, Article ID 219789, 4 pages http://dx.doi.org/1.1155/214/219789 Clinical Study The Impact of the Introduction of MELD on the Dynamics of the Liver Transplantation Waiting List in São Paulo,
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationLiver and intestine transplantation: summary analysis,
American Journal of Transplantation 25; 5 (Part 2): 916 933 Blackwell Munksgaard Blackwell Munksgaard 25 Liver and intestine transplantation: summary analysis, 1994 23 Douglas W. Hanto a,, Thomas M. Fishbein
More informationTrapianto di fegato e organi solidi. Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine
Trapianto di fegato e organi solidi Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine Case 1 55-yr old white woman Alcoholic cirrhosis (CTP score 11, MELD 24, status UNOS
More informationMore than 350 million people worldwide are
Double-Dose Accelerated Hepatitis B Vaccine in Patients With End-Stage Liver Disease Mehmet Arslan, * Russell H. Wiesner, * Corey Sievers, * Kathleen Egan, and Nizar N. Zein * The aims of this study are
More informationTHE MODEL FOR END-STAGE
ORIGINAL CONTRIBUTION Disparities in Liver Transplantation Before and After Introduction of the MELD Score Cynthia A. Moylan, MD Carla W. Brady, MD, MHS Jeffrey L. Johnson, MS Alastair D. Smith, MB, ChB
More informationErratum to: Int J Hematol (2014) 99: DOI /s
Int J Hematol (216) 13:725 729 DOI 1.17/s12185-16-1987-1 ERRATUM Erratum to: Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationOutcomes in partial liver transplantation: deceased donor split-liver vs. live donor liver transplantation
DOI:10.1111/j.1477-2574.201360.x HPB ORIGINAL ARTICLE Outcomes in partial liver transplantation: deceased donor split-liver vs. live donor liver transplantation Reza F. Saidi, Nicolas Jabbour, YouFu Li,
More informationHow to improve long term outcome after liver transplantation?
How to improve long term outcome after liver transplantation? François Durand Hepatology & Liver Intensive Care University Paris Diderot INSERM U1149 Hôpital Beaujon, Clichy PHC 2018 www.aphc.info Long
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationCharacteristics Associated with Liver Graft Failure: The Concept of a Donor Risk Index
American Journal of Transplantation 2006; 6: 783 790 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationIncreased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant
ORIGINAL ARTICLE July-August, Vol. 15 No. 4, 2016: 545-549 545 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationImpact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index
LIVER TRANSPLANTATION 14:321-326, 2008 ORIGINAL ARTICLE Impact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index Amy A. Dan, 1,2 Jillian B. Kallman, 1,2
More informationResearch Article Impact of Recipient and Donor Obesity Match on the Outcomes of Liver Transplantation: All Matches Are Not Perfect
Journal of Transplantation Volume 2016, Article ID 9709430, 9 pages http://dx.doi.org/10.1155/2016/9709430 Research Article Impact of Recipient and Donor Obesity Match on the Outcomes of Liver Transplantation:
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationUK Liver Transplant Audit
November 2012 UK Liver Transplant Audit In patients who received a Liver Transplant between 1 st March 1994 and 31 st March 2012 ANNUAL REPORT Advisory Group for National Specialised Services Prepared
More informationEarly Allograft Dysfunction After Liver Transplantation Is Associated With Short- and Long-Term Kidney Function Impairment
American Journal of Transplantation 2016; 16: 850 859 Wiley Periodicals Inc. Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.13527
More informationLiver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
More informationShould Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?
American Journal of Transplantation 2008; 8: 2056 2061 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationDe novo malignancy occurs more commonly after. Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation
GASTROENTEROLOGY 2009;137:2010 2017 Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation KYMBERLY D. S. WATT,* RACHEL A. PEDERSEN, WALTER K. KREMERS, JULIE K. HEIMBACH,
More informationORIGINAL ARTICLE LIVER TRANSPLANTATION 17: , 2011
LIVER TRANSPLANTATION 17:789-797, 2011 ORIGINAL ARTICLE Outcomes of Adult Living Donor Liver Transplantation: Comparison of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study and the National
More informationORTHOTOPIC LIVER TRANSPLANTATION IN HIGH-RISK PATIENTS
February 27. 1998 GAYOWSKI ET AL. 499 B virus core antibody on incidence of posttransfusion hepatitis. Lancet 1991; 338: 1040. 18. Chazouilleres O. Mamish D, Kim M. et al. "Occult" hepatitis B virus as
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationORIGINAL ARTICLE Gastroenterology & Hepatology INTRODUCTION
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2013.28.8.1207 J Korean Med Sci 2013; 28: 1207-1212 The Model for End-Stage Liver Disease Score-Based System Predicts Short
More informationIncreasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients
Accepted Manuscript Increasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients George Cholankeril, MD, Andrew A. Li, MD, Brittany B. Dennis, PhD, Alice E. Toll, MS, Donghee
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More information